3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
7
Recruiting
3
Withdrawn
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Colorectal Neoplasms
30
Carcinoma, Hepatocellular
17
Ovarian Neoplasms
14
Fallopian Tube Neoplasms
10
Carcinoma, Non-Small-Cell Lung
9
Neoplasms
8
Glioblastoma
7
Liver Neoplasms
6
Lung Neoplasms
5
Colonic Neoplasms
5
Breast Neoplasms
5
Neoplasm Metastasis
4
Carcinoma, Renal Cell
4
Brain Neoplasms
4
Stomach Neoplasms
3
Rectal Neoplasms
3
Melanoma
3
Carcinoma, Ovarian Epithelial
3
Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Nasopharyngeal Neoplasms
2
Nasopharyngeal Carcinoma
2
Lymphoid Interstitial Pneumonia
2
Colorectal Cancer Metastatic
2
Brenner Tumor
2
Advanced Solid Tumors
2
Adenocarcinoma, Mucinous
2
Virus Diseases
1
Interventions
Carboplatin
15
durvalumab
14
Etoposide
14
pembrolizumab
9
atezolizumab
9
Cisplatin
9
Topotecan
8
Nivolumab
7
Specimen Handling
6
olaparib
4
berzosertib
4
Temozolomide
4
Magnetic Resonance Spectroscopy
4
AMG 757
4
tremelimumab
3
Radiotherapy
3
Radiosurgery
3
PM 01183
3
Ipilimumab
3
Docetaxel
3
Biopsy
3
niraparib
2
lenvatinib
2
cabozantinib
2
Platinum
2
Irinotecan
2
Fulvestrant
2
veliparib
1
tislelizumab
1
tazemetostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Small Cell Lung Carcinoma
×
Bevacizumab
×
Clear all
NCT02734004
2026-04-20
MEDIOLA
AstraZeneca
Phase 1/2
Active not recruiting
264 enrolled
32 charts